An Economic Modeling Study of Helicobacter pylori Eradication: Comparison of Dual Priming Oligonucleotide-Based Multiplex Polymerase Chain Reaction and Empirical Treatment = An Economic Modeling Study of Helicobacter pylori Eradication: Comparison of Dual Priming Oligonucleotide-Based Multiplex Polymerase Chain Reaction and Empirical Treatment

다국어 초록 (Multilingual Abstract)

Background/Aims: Dual priming oligonucleotide-based multiplex polymerase chain reaction (DPO-based PCR) can detect the presence of clarithromycin resistance without culture. The aim of this study was to investigate the cost-effectiveness of DPO-based PCR for Helicobacter pylori eradication. Methods: From 2015 to 2016, medical records of patients who received H. pylori eradication therapy were analyzed. Patients were divided into two groups: tailored group patients who were treated based on DPO-based PCR and empirical group patients. Eradication rate and medical cost, including diagnostic tests, eradication regimens, and ¹³C-urea breath tests, were compared between the two groups. Cost for one successful eradication was calculated in each group. The expected cost of eradication for empirical treatment was investigated by varying the treatment duration and eradication rate. Results: A total of 527 patients were analyzed (tailored group 208, empirical group 319). The eradication success rate of the first-line therapy was higher in the tailored group compared to that in the empirical group (91.8% vs 72.1%, p<0.01). The total medical cost for each group was 114.8±14.1 U.S. dollars (USD) and 85.8±24.4 USD, respectively (p<0.01). The total medical costs for each ultimately successful eradication in the tailored group and in the empirical group were 120.0 USD and 92.4 USD, respectively. The economic modeling expected cost of a successful eradication after a 7- or 14-day empirical treatment was 93.8 to 111.4 USD and 126.3 to 149.9 USD, respectively. Conclusions: Based on economic modeling, the cost for a successful eradication using DPO-based PCR would be similar or superior to the expected cost of a successful eradication with a 14-day empirical treatment when the first-line eradication rate is ≤80%. (Gut Liver 2018;12:648-654)

참고문헌 (Reference)

1 Suzuki S, "The efficacy and tolerability of a triple therapy containing a potassiumcompetitive acid blocker compared with a 7-day PPI-based lowdose clarithromycin triple therapy" 111 : 949-956, 2016

2 Sasaki H, "Ten-year trend of the cumulative Helicobacter pylori eradication rate for the ‘Japanese eradication strategy’" 88 : 272-278, 2013

3 Toracchio S, "Role of antimicrobial susceptibility testing on efficacy of triple therapy in Helicobacter pylori eradication" 14 : 1639-1643, 2000

4 Chen Q, "Rescue therapy for Helicobacter pylori eradication: a randomized non-inferiority trial of amoxicillin or tetracycline in bismuth quadruple therapy" 111 : 1736-1742, 2016

5 Bahin FF, "Prophylactic clipping for the prevention of bleeding following wide-field endoscopic mucosal resection of laterally spreading colorectal lesions: an economic modeling study" 48 : 754-761, 2016

6 Hu Y, "Primary antibiotic resistance of Helicobacter pylori in China" 62 : 2017

7 Lee JW, "Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012" 18 : 206-214, 2013

8 Romano M, "Pretreatment antimicrobial-susceptibility testing in the eradication of H. pylori infection" 95 : 3317-3318, 2000

9 Park CS, "Pretreatment antimicrobial susceptibility- guided vs. clarithromycin-based triple therapy for Helicobacter pylori eradication in a region with high rates of multiple drug resistance" 109 : 1595-1602, 2014

10 Yuan Y, "Optimum duration of regimens for Helicobacter pylori eradication" (12) : CD008337-, 2013

11 Liou JM, "Levofloxacin sequential therapy vs levofloxacin triple therapy in the second-line treatment of Helicobacter pylori: a randomized trial" 111 : 381-387, 2016

12 Graham DY, "How to effectively use bismuth quadruple therapy: the good, the bad, and the ugly" 44 : 537-563, 2015

13 장현주, "Helicobacter pylori 감염 1차 치료를 위한 삼제요법과 사제요법의 제균 효과" 대한소화기학회 46 (46): 368-372, 2005

14 Megraud F, "Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption" 62 : 34-42, 2013

15 Filipec Kanizaj T, "Helicobacter pylori eradication therapy success regarding different treatment period based on clarithromycin or metronidazole tripletherapy regimens" 14 : 29-35, 2009

16 Shin WG, "Eradication rates of Helicobacter pylori in Korea over the past 10 years and correlation of the amount of antibiotics use: nationwide survey" 21 : 266-278, 2016

17 Lee HJ, "Eradication of Helicobacter pylori according to 23S ribosomal RNA point mutations associated with clarithromycin resistance" 208 : 1123-1130, 2013

18 Liu Q, "Efficacy of real-time PCR-based detection of Helicobacter pylori infection and genotypic resistanceguided quadruple therapy as the first-line treatment for functional dyspepsia with Helicobacter pylori infection" 27 : 221-225, 2015

19 Jung YS, "Efficacy of Helicobacter pylori eradication therapies in Korea: a systematic review and network meta-analysis" 22 : e12389-, 2017

20 Bae SE, "Effect of Helicobacter pylori eradication on metachronous recurrence after endoscopic resection of gastric neoplasm" 109 : 60-67, 2014

21 Woo HY, "Dual-priming oligonucleotidebased multiplex PCR for the detection of Helicobacter pylori and determination of clarithromycin resistance with gastric biopsy specimens" 14 : 22-28, 2009

22 Lehours P, "DPO multiplex PCR as an alternative to culture and susceptibility testing to detect Helicobacter pylori and its resistance to clarithromycin" 11 : 112-, 2011

23 Liou JM, "Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial" 388 : 2355-2365, 2016

24 Kim BG, "Comparison of 7-day and 14-day proton pump inhibitor-containing triple therapy for Helicobacter pylori eradication: neither treatment duration provides acceptable eradication rate in Korea" 12 : 31-35, 2007

25 Hwang TJ, "Change in antibiotic resistance of Helicobacter pylori strains and the effect of A2143G point mutation of 23S rRNA on the eradication of H. pylori in a single center of Korea" 44 : 536-543, 2010

26 Cosme A, "Antimicrobial susceptibility- guided therapy versus empirical concomitant therapy for eradication of Helicobacter pylori in a region with high rate of clarithromycin resistance" 21 : 29-34, 2016

27 Horiki N, "Annual change of primary resistance to clarithromycin among Helicobacter pylori isolates from 1996 through 2008 in Japan" 14 : 86-90, 2009

28 Chey WD, "ACG clinical guideline: treatment of Helicobacter pylori onfection" 112 : 212-239, 2017

29 Calvet X, "A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection" 14 : 603-609, 2000